Comparative effectiveness of pegfilgrastim biosimilars vs originator for prevention of febrile neutropenia: A retrospective cohort study

BACKGROUND: Real-world evidence on the comparative effectiveness of pegfilgrastim biosimilars compared with the originator product is limited. OBJECTIVE: To compare the risk of febrile neutropenia (FN) among users of pegfilgrastim biosimilars (pegfilgrastim-jmdb and pegfilgrastim-cbqv) and the origi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ching-Yu, Vouri, Scott M, Park, Haesuk, Heldermon, Coy D, Brown, Joshua D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387906/
https://www.ncbi.nlm.nih.gov/pubmed/36705287
http://dx.doi.org/10.18553/jmcp.2023.29.2.119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387906/
https://www.ncbi.nlm.nih.gov/pubmed/36705287
http://dx.doi.org/10.18553/jmcp.2023.29.2.119

Ejemplares similares